References
- Feldman SR. Psoriasis treatment. CUIT: Prob. DermatoL 10,1–40 (1998).
- Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am. Acad. DermatoL 49,271–275 (2003).
- Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am. Acad. DermatoL 41,401–407 (1999).
- •There is extensive focus on the objective severity of psoriasis as determined by the clinician. Provides a reminder of the significance of psoriasis by highlighting the overwhelming impact psoriasis can have on well-being.
- Rapp SR, Exum ML, Reboussin DM, Feldman SR, Fleischer A, Clark A. The physical, psychological and social impact of psoriasis. J. Health PsychoL 2,525–537 (1997).
- Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. DermatoL 137, 280–284 (2001).
- Liem WH, McCullough JL, Weinstein GD. Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis 55,306–310 (1995).
- •Helpful to clinicians who are uncertain of how to advance through the therapeutic ladder for moderate-to-severe psoriasis.
- Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin. Exp. DermatoL 26,314–320 (2001).
- Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. Am. Acad. DermatoL 49, S44—S50 (2003).
- Sander HM, Morris LF, Phillips CM, Harrison PE, Menter A. The annual cost of psoriasis. J Am. Acad. DermatoL 28, 422–425 (1993).
- Feldman SR, Fleischer AB Jr, Reboussin DM et aL The economic impact of psoriasis increases with psoriasis severity. I Am. Acad. DermatoL 37,564–569 (1997).
- Housman TS, Rohrback JM, Fleischer AB Jr, Feldman SR. Phototherapy utilization for psoriasis is declining in the United States. J. Arn. Acad. DermatoL 46,557–559 (2003).
- Lowe NJ, Prystowsky JH, Bourget T et aL Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am. Acad. DermatoL 24, 591–594 (1991).
- Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporin in moderate-to-severe chronic plaque psoriasis. N Engl. J. Med. 349,658–665 (2003).
- Robert C, Kupper TS. Inflammatory skin diseases, T-cells, and immune surveillance. N. EngL J. Med. 341,1817–1828.
- Bonifati C, Ameglio E Cytokines in psoriasis. Int. J DermatoL 38,241–251 (1999).
- Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357,1842–1847 (2001).
- Gottlieb AB, matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch. DermatoL 139,1627–1632 (2003).
- Gottlieb AB, Masud S, Ramamurthi R et al. Pharmacodynamic and pharmacokinetic response to antitumor necrosis factor-a monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am. Acad. DermatoL 48,68–75 (2003).
- ••Pivotal clinical trial design and data. Thecontent is vital to a clinician wishing to use biologics for their psoriasis patients.
- Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am. Acad. DermatoL 46,886–891 (2002).
- Stern RS. Inpatient hospital care for psoriasis: a vanishing practice in the United States. J. Am. Acad. DermatoL 49,445–450 (2003).
- Gladdman DD. Psoriatic arthritis. In: Oxford Textbook of Rheumatology Maddison PJ, Isneberg DA, Glass DN (Eds). Oxford Univesity Press, Oxford, UK, 1071 (1988).
- Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N EngL J. Med. 349,2014–2022 (2003).
- ••Pivotal clinical trial design and data. The content is vital to a clinician wishing to use biologics for their psoriasis patients.
- Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled Phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am. Acad. DermatoL 47,821–833 (2002).
- ••Pivotal clinical trial design and data. Thecontent is vital to a clinician wishing to use biologics for their psoriasis patients.
- Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. DermatoL 139,719–727 (2003).
- Ortonne J. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J. Eur. Acad. DermatoL VenereoL 17,12–16 (2003).
- Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. JAMA 290,3073–3080 (2003).
- ••Pivotal clinical trial design and data. Thecontent is vital to a clinician wishing to use biologics for their psoriasis patients.
Website
- Psoriasis Foundation. When are patients candidates for phototherapy or systemic treatments (including biologics)? 2003. www.psoriasis.orgifiles/pdfsimedicalpros/ 2003_systemicsdiagram.pdf (Accessed September 2004)